An international consortium published complementary papers in Nature Communications describing engineered bacterial strains that overcome long‑standing biosynthetic bottlenecks in doxorubicin production. The teams identified and rewired metabolic and enzymatic steps that limited commercial biosynthesis, enabling markedly higher yields of the anthracycline chemotherapy. The lead sentence: scientists engineered microbial pathways and key enzymes to restore and scale natural-product biosynthesis of doxorubicin after five decades of limits. The work combines genomic mining, heterologous expression and synthetic biology to address manufacturing supply constraints for a cornerstone chemotherapy, with implications for more reliable global drug supply chains.